Project Grant R41HL176277
Award Date
9/5/24
Completion Date
9/4/25
Dollars Obligated
$390K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Lexington, SC, USA
Similar Awards
The federal Project Grant award R33HL175682, titled "Peptides for the Treatment of Pulmonary Fibrosis," was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The $464,121 award to the Medical University of South Carolina aims to simultaneously test and identify lead peptide candidates that have demonstrated anti-fibrotic effects in preclinical models of lung fibrosis. The project will further characterize...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) totaling $1,182,632 supports the development of a novel small molecule inhibitor, HS-276, as a potential treatment for systemic sclerosis-associated interstitial lung disease (SSc-ILD). The awardee, Eydis Bio, Inc., is conducting in vivo pharmacodynamic studies in murine lung fibrosis models, evaluating the safety of HS-276 in opportunistic disease models, and...
This $805,845 four-year federal Project Grant award (R01HL175948) from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and testing of novel "lung precision drug delivery systems" (LPDDS) to target lung fibrosis. The Proteogenomics Research Institute for Systems Medicine, a non-profit research organization in La Jolla, California, is the grant recipient. The key goals of this project are to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $299,295 to Fibrobiologics LLC to support the preclinical development of a novel therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF). The funding, provided through the Cardiovascular Diseases Research program (CFDA 93.837), will enable Fibrobiologics to determine the antifibrotic activity of the peptide M10 in primary lung fibroblasts from IPF patients and evaluate its efficacy in two...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded a $306,748 Project Grant to Mechanobiologix LLC. The funding supports research to develop a stiffness-based drug discovery platform for Idiopathic Pulmonary Fibrosis (IPF), a progressive lung disease. The project aims to integrate micro- and macro-scale stiffness measurements with traditional IPF discovery endpoints, and demonstrate proof-of-concept in...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Novomedix LLC a $306,872 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and commercialize a novel, safer, and more effective therapy for the treatment of idiopathic pulmonary fibrosis (IPF) and other progressive pulmonary fibrotic diseases. The grant supports Novomedix's research on a series of small molecule compounds that inhibit myofibroblast activation and differentiation, potentially...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $299,999 to Altay Therapeutics, Inc. to develop a STAT3 inhibitor for treating lung fibrosis associated with systemic sclerosis (SSc-ILD). The key objectives are to: 1) evaluate the cytotoxicity and ability of the STAT3 inhibitor to block STAT3 target genes in normal and SSc-ILD patient fibroblasts; 2) determine the...
This federal Project Grant award, totaling $1,909,362, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The funding supports the advanced preclinical development of NOX4 inhibitors as a novel therapeutic approach for pulmonary fibrosis, a major health problem with limited treatment options. The award recipient, Fibronox, L.L.C., a woman-owned small business, is collaborating with Emory University to validate...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $286,739.00 to Fibronox, L.L.C., a woman-owned small business, to evaluate the potential of repurposing FDA-approved Nrf2 activators as an inhaled therapy for idiopathic pulmonary fibrosis (IPF). The key objectives are to assess the efficacy of three Nrf2 activators in human ex vivo lung models, characterize their pharmacokinetic...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), totals $542,402 and will be conducted from April 1, 2025 to March 31, 2026. The grant aims to identify small molecules that can reverse profibrotic gene signatures in idiopathic pulmonary fibrosis (IPF), a debilitating lung disease with no effective treatments. The researchers will use large-scale single-cell RNA sequencing and artificial...